Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H44O2 |
| Molecular Weight | 400.6371 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3/C[C@@H](O)CCC3=C
InChI
InChIKey=JWUBBDSIWDLEOM-WIFPIRAHSA-N
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12+/t20-,23+,24-,25+,27-/m1/s1
| Molecular Formula | C27H44O2 |
| Molecular Weight | 400.6371 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4310770
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4310770
Calcifediol (25-Hydroxyvitamin D3 or 25-hydroxycholecalciferol) is a biologically active vitamin D3 metabolite. It is concluded that the liver is the major if not the only physiologic site of hydroxylation of vitamin D3 into calcifediol. Calcifediol is a prohormone of the active form of vitamin D3, calcitriol (1,25-dihydroxyvitamin D3). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis. RAYALDEE (calcifediol) extended-release capsules is indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4300699
Curator's Comment: 1968
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1977 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19944755 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | RAYALDEE Approved UseCalcifediol indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL Launch Date2016 |
|||
| Primary | CALDEROL Approved UseUnknown Launch Date1980 |
|||
| Primary | CALDEROL Approved UseUnknown Launch Date1980 |
|||
| Primary | CALDEROL Approved UseUnknown Launch Date1980 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
73.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24516879/ |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIFEDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1704.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24516879/ |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIFEDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24516879/ |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIFEDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24516879/ |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CALCIFEDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. | 2011-02-03 |
|
| Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. | 2010-03-30 |
|
| Functional evolution of the vitamin D and pregnane X receptors. | 2007-11-12 |
|
| Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. | 2006-08-05 |
|
| Androgen enhances the antiproliferative activity of vitamin D3 by suppressing 24-hydroxylase expression in LNCaP cells. | 2006-04 |
|
| Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. | 2005-12-30 |
|
| Vitamin D(3) metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol. | 2005-08-01 |
|
| Overview of general physiologic features and functions of vitamin D. | 2004-12 |
|
| Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients. | 2004 |
|
| De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. | 2003-09-26 |
|
| Kidney microsomal 25- and 1alpha-hydroxylase in vitamin D metabolism: catalytic properties, molecular cloning, cellular localization and expression during development. | 2002-02-28 |
|
| A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. | 1999-09-01 |
|
| Calcidiol and PTH levels in women attending an osteoporosis program. | 1999-04 |
|
| Proteins in the heat shock-70 family specifically bind 25-hydroxyvitamin D3 and 17beta-estradiol. | 1998-04 |
|
| Vitamin D3 compounds regulate human immunodeficiency virus type 1 replication in U937 monoblastoid cells and in monocyte-derived macrophages. | 1993-02 |
|
| 1 alpha,25-dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1. | 1991-04-30 |
|
| Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. | 1990-11 |
|
| The effect of vitamin D status on cutaneous sterologenesis in vivo and in vitro. | 1987-09-14 |
|
| Hypercalcemia in 25 OH D3 treated patients receiving a calcium exchange resin. | 1985-06 |
|
| Tubular aggregates in a case of osteomalacic myopathy due to anticonvulsant drugs. | 1984-01-01 |
|
| Interrelationship of serum 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D in juvenile renal osteodystrophy after therapy with 25-hydroxyvitamin D3. | 1982 |
|
| Determination of vitamin D and its metabolites in plasma from normal and anephric man. | 1979-07-15 |
Patents
Sample Use Guides
The initial dose of RAYALDEE (calcifediol) extended-release capsules is 30 mcg administered orally once daily at bedtime. Serum calcium should be below 9.8 mg/dL before initiating treatment.
Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and intact parathyroid hormone (PTH) 3 months after starting therapy or changing dose.
Increase the dose to 60 mcg once daily after 3 months if intact PTH is above the treatment goal. Ensure serum calcium is below 9.8 mg/dL, phosphorus is below 5.5 mg/dL and 25-hydroxyvitamin D is below 100 ng/mL before increasing the dose.
Suspend dosing if intact PTH is persistently abnormally low, serum calcium is consistently above the normal range or serum 25 hydroxyvitamin D is consistently above 100 ng/mL
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26178144
Vitamin D metabolites down-regulated stimulated IL-8 only in those hyperinflammatory monocyte-derived macrophages, and only when used at high doses (>100 nM for Calcifediol).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:02:59 GMT 2025
by
admin
on
Mon Mar 31 21:02:59 GMT 2025
|
| Record UNII |
SN331791VY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SN331791VY
Created by
admin on Mon Mar 31 21:02:59 GMT 2025 , Edited by admin on Mon Mar 31 21:02:59 GMT 2025
|
PRIMARY | |||
|
252-891-2
Created by
admin on Mon Mar 31 21:02:59 GMT 2025 , Edited by admin on Mon Mar 31 21:02:59 GMT 2025
|
PRIMARY | |||
|
36149-00-5
Created by
admin on Mon Mar 31 21:02:59 GMT 2025 , Edited by admin on Mon Mar 31 21:02:59 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
6506392
Created by
admin on Mon Mar 31 21:02:59 GMT 2025 , Edited by admin on Mon Mar 31 21:02:59 GMT 2025
|
PRIMARY | |||
|
1233749-00-2
Created by
admin on Mon Mar 31 21:02:59 GMT 2025 , Edited by admin on Mon Mar 31 21:02:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|